Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Significant Decrease in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 143,564 shares, a decline of 46.6% from the September 15th total of 268,742 shares. Based on an average daily trading volume, of 239,833 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.1% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Loop Capital set a $1.00 price target on Xtant Medical in a research report on Wednesday, September 2nd. Two research analysts have rated the stock with a Buy rating. According to data from MarketBeat, Xtant Medical has an average rating of “Buy” and a consensus price target of $1.00.

Hedge Funds Weigh In On Xtant Medical

A hedge fund recently bought a new position in Xtant Medical stock. AWM Investment Company Inc. acquired a new stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 5,976,910 shares of the medical device company’s stock, valued at approximately $2,516,000. AWM Investment Company Inc. owned approximately 4.26% of Xtant Medical at the end of the most recent quarter. Hedge funds and other institutional investors own 69.33% of the company’s stock.

Xtant Medical Stock Performance

Xtant Medical stock traded down $0.02 during midday trading on Thursday, hitting $0.30. 124,293 shares of the company were exchanged, compared to its average volume of 644,174. Xtant Medical has a fifty-two week low of $0.27 and a fifty-two week high of $0.95. The firm has a market capitalization of $42.48 million, a PE ratio of -3.78 and a beta of -0.20. The business has a fifty day simple moving average of $0.35 and a two-hundred day simple moving average of $0.42. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.05 and a current ratio of 2.16.

Xtant Medical (NYSEAMERICAN:XTNT) last released its quarterly earnings data on Tuesday, August 11th. The medical device company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.05). The firm had revenue of $23.03 million during the quarter, compared to analysts’ expectations of $24.88 million. Xtant Medical had a negative net margin of 10.17% and a negative return on equity of 23.45%.

About Xtant Medical

Xtant Medical Holdings, Inc is a medical technology company focused on developing, manufacturing and distributing products used in orthopedic and spinal procedures. Its portfolio is designed to support bone growth, spinal fusion and the repair or reconstruction of musculoskeletal structures.

The company offers a range of biologic products, including human tissue allografts, demineralized bone matrix and other bone-graft substitutes. It also provides implantable devices and surgical instruments for spine and orthopedic applications, including products used in interbody fusion and spinal fixation procedures.

Xtant Medical is headquartered in Belgrade, Montana, and serves the U.S.